Kevin Love

According to FutureWise analysis the market for Carfilzomib in 2023 is US$ 0.2 billion, and is expected to reach US$ 0.25 billion by 2031 at a CAGR of 2.80% Carfilzomib, marketed under the trade name Kyprolis, is an anti-cancer medication derived from the naturally occurring compound epoxomicin. It is notable for its ability to bind to the 20-S proteasome and inhibit chymotrypsin activity, making it an effective treatment for blood cancers, particularly multiple myeloma. Carfilzomib is typically administered in combination with other medications such as lenalidomide or dexamethasone to enhance its therapeutic effects. One of the significant advantages of Carfilzomib is its increased efficacy compared to traditional cancer therapies, along with a relatively favorable side effect profile. However, some patients may experience side effects such as severe bloating, blood in the urine, chest pain, nausea, diarrhea, muscle pain, and headaches. While most side effects can alleviate within a ... Continue reading →

According to FutureWise analysis the market for Caspofungin in 2023 is US$ 0.51 billion, and is expected to reach US$ 0.61 billion by 2031 at a CAGR of 2.20%. Caspofungin is a lipopeptide antifungal medication that specifically targets the enzyme known as β-D-glucan synthase, which plays a crucial role in maintaining the integrity of the fungal cell wall. This drug is part of a novel class of antifungals known as Echinocandins and has been approved by the FDA for clinical use. It is administered intravenously. The market for caspofungin is projected to undergo substantial growth due to a variety of factors. There has been a notable increase in the incidence of invasive candidiasis, correlating with an uptick in the utilization of echinocandins. Furthermore, enhancements in purchasing power and disposable income in developing countries, coupled with heightened awareness regarding the preventive measures against various microbial infections, are anticipated to bolster market demand. ... Continue reading →

According to FutureWise analysis the market for Carfilzomib in 2023 wasUS$ 0.2 billion, and is expected to reach US$ 0.25 billion by 2031 at a CAGR of 2.80%. Carfilzomib (also known as Kyprolis) is an anti-cancer medication that is derived from epoxomicin. This is a naturally occurring compound. Carfilzomib is a drug that binds to the 20-S proteasome. It also inhibits chymotrypsin activity. Injections of Carfilzomib are combined with drugs like lenalidomide or dexamethasone to treat blood cancer and multiple myeloma. The drug is very viable but it has few side effects. These include severe bloating, blood in the urine, and chest pain. Carfilzomib can also be divided based on type and strength. A 10mg injection is the most potent and a 60mg injection is the strongest. Carfilzomib has many advantages over traditional cancer treatment therapies, including increased efficacy and fewer side effects. Carfilzomib, a new proteasome inhibitor, exhibits high selectivity for the N-terminal and ... Continue reading →

According to FutureWise analysis the market for cath lab in 2023 is US$ 48.59 billion, and is expected to reach US$ 75.24 billion by 2031 at a CAGR of 5.60%. A catheterization lab, commonly referred to as a cath lab, is a specialized medical facility equipped with diagnostic imaging technology that allows for the visual examination of the heart's arteries and chambers. Most catheterization labs operate as "single-plane" facilities, featuring one X-ray generator and an X-ray image intensifier for fluoroscopic imaging. Historically, older cath labs recorded information on cine films, while modern labs have transitioned to digital technology. Modern digital cardiac catheterization laboratories employ advanced flat panel detectors and typically function as biplane systems featuring dual X-ray sources. The staffing structure of cardiac catheterization laboratories generally consists of multidisciplinary teams comprised of various healthcare professionals. This team typically ... Continue reading →

According to FutureWise analysis the market for cath lab in 2023 is US$ 48.59 billion, and is expected to reach US$ 75.24 billion by 2031 at a CAGR of 5.60%. A catheterization lab, commonly referred to as a cath lab, is a specialized medical facility equipped with diagnostic imaging technology that allows for the visual examination of the heart's arteries and chambers. Most catheterization labs operate as "single-plane" facilities, featuring one X-ray generator and an X-ray image intensifier for fluoroscopic imaging. Historically, older cath labs recorded information on cine films, while modern labs have transitioned to digital technology. Modern digital cardiac catheterization laboratories employ advanced flat panel detectors and typically function as biplane systems featuring dual X-ray sources. The staffing structure of cardiac catheterization laboratories generally consists of multidisciplinary teams comprised of various healthcare professionals. This team typically ... Continue reading →

According to FutureWise analysis the market for Cardiac Resynchronization Therapy in 2023 is US$ 4.48 billion, and is expected to reach US$ 6.68 billion by 2031 at a CAGR of 5.10%. The market for Cardiac Resynchronization Therapy Devices (CRT-D) is expected to lead in dominance throughout the forecast period. A study published in the Journal of Cardiovascular Electrophysiology indicates that more than half of the implants for CRT products utilize CRT-D devices. Significant growth is anticipated in the Latin America and Asia Pacific regions, which are expected to contribute over 25% of total revenue. This growth is driven by the rapid industrial development of key market players in distribution and manufacturing sectors. Additionally, the ongoing need for optimized operational efficiency and competitive pricing is likely to enable companies to enhance their market presence in emerging economies such as Mexico and India. In countries like Japan, the increasing adoption of quadripolar ... Continue reading →

According to FutureWise analysis, the market for Age Related Macular Degeneration Drug is estimated to be US$ 11.29 billion in 2023 and is expected to reach US$ 19.57 billion by 2031 at a CAGR of 7.1% over the forecast period of 2025-2033.. Age-related macular degeneration (AMD) is a prevalent eye condition that primarily affects older adults, leading to blurred central vision due to damage to the macula—the vital area of the retina responsible for processing detailed visual information. AMD has two main types: dry AMD, also known as atrophic AMD, and wet AMD, termed advanced neovascular AMD. Dry AMD is the more common form, characterized by a gradual thinning of the macula as part of the aging process. This condition progresses through three distinct stages: early, intermediate, and late. In contrast, wet age-related macular degeneration (AMD) is less prevalent but more aggressive, often leading to rapid vision deterioration. This form of AMD occurs exclusively in its late ... Continue reading →

According to FutureWise analysis, the market for African Horse Sickness Treatment is estimated to be US$ 0.84 billion in 2023 and is expected to reach US$ 2.98 billion by 2031 at a CAGR of 17.20% over the forecast period of 2025-2033. African horse sickness (AHS) is a serious viral disease that affects equines and can be fatal in many cases. It is caused by the African horse sickness virus, which consists of nine distinct serotypes. The disease is highly contagious and poses significant health risks to horse populations. Although AHS primarily targets horses, it can also affect mules, donkeys, and zebras. Although other species such as elephants, camels, and dogs can contract the virus, they typically do not exhibit symptoms, often becoming infected through the consumption of contaminated horse meat. The disease is spread not directly between animals, but through insect vectors, with Culicoides midges being the primary carriers. Other vectors include various mosquitoes (such as Culex, ... Continue reading →

According to FutureWise analysis the market for aflatoxicosis treatment in 2023 was US$ 0.28 billion, and is expected to reach US$ 0.38 billion by 2031 at a CAGR of 4%. Aflatoxicosis is an important mycotoxin issue that significantly impacts agriculture and livestock. It is primarily caused by aflatoxins, which are potent hepatotoxins that can develop in animal feed during high temperatures, particularly in the presence of insect damage. The fungi Aspergillus flavus and Aspergillus parasiticus are known to infest crops like corn, cottonseed, peanuts, and various nuts, producing high levels of aflatoxins, with aflatoxin B1 recognized as the most toxic variant. When animals are exposed to aflatoxins, the toxins are metabolized into an epoxide form in the liver, where they can bind to vital macromolecules, including nucleic acids. This can lead to several adverse health effects, such as carcinogenesis, immunosuppression, mutagenesis, teratogenesis, and liver damage, which may result in ... Continue reading →

According to FutureWise analysis, the market for Aerosol Delivery Devices is expected to reach US$ 57.02 billion by 2031 at a CAGR of 5.12% over the forecast period of 2025-2033. The delivery of aerosol medication directly to the airways is crucial for the emergency treatment and long-term management of chronic lung diseases such as COPD and asthma in both adults and children. Over the past sixty years, aerosol delivery devices have undergone remarkable advancements. They have evolved from simple pressurized metered-dose inhalers (pMDIs) and nebulizers to an array of sophisticated inhalation devices. This includes options such as dry powder inhalers, soft mist inhalers, and valved holding chambers, each designed to improve the efficiency and ease of medication delivery. Additionally, the introduction of smart inhalers and nebulizers has further enhanced patient medication adherence and self-administration capabilities. Despite these advancements, many challenges regarding optimal ... Continue reading →